Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis.

Jocelin Huang, MD, Chin-Yang Li, MD, Ruben A. Mesa, MD, Wenting Wu, PhD, Curtis A. Hanson, MD, Animesh D. Pardanani, MD, PhD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 554.

https://doi.org/10.1182/blood.V110.11.554.554

Published: 2007

Journal Articles

Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL.

Jocelin Huang, MD, Terra L. Lasho, MT(ASCP), Chin Yang Li, MD, Animesh D. Pardanani, MD, PhD, Ruben A. Mesa, MD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 3555.

https://doi.org/10.1182/blood.V110.11.3555.3555

Published: 2007

Journal Articles

Perioperative Outcome of Patients with Acquired Factor X Deficiency Associated with AL Amyloidosis: The Mayo Clinic Experience.

Carrie Thompson, MD, Robert Kyle, MD, Morie Gertz, MD, Martha Lacy, MD, John A. Heit, MD, Rajiv Pruthi, MD, Animesh D. Pardanani, MD

Blood (2007) 110 (11): 3965.

https://doi.org/10.1182/blood.V110.11.3965.3965

Published: 2007

Journal Articles

Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.

Animesh D. Pardanani, MD, PhD, Rhett P. Ketterling, MD, Chin-Yang Li, MD, Alexandra P. Wolanskyj, MD, Michelle A. Elliott, MD, John K. Camoriano, MD, Joseph H. Butterfield, MD, Gordon W. Dewald, PhD, Ayalew Tefferi, MD

Blood (2005) 106 (11): 2590.

https://doi.org/10.1182/blood.V106.11.2590.2590

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis.

Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL.

Perioperative Outcome of Patients with Acquired Factor X Deficiency Associated with AL Amyloidosis: The Mayo Clinic Experience.

Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.

Email alerts

ASH Publications

American Society of Hematology

Update search

Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis.

Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL.

Perioperative Outcome of Patients with Acquired Factor X Deficiency Associated with AL Amyloidosis: The Mayo Clinic Experience.

Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only